Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Lilly’s retatrutide shows 28.3% weight loss, but increased side effects
Eli Lilly’s experimental triple hormone receptor agonist, retatrutide, has recently captured significant attention within the medical and pharmaceutical communities following…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Eli Lilly’s Retatrutide Demonstrates Superior Weight Loss Efficacy Amidst Elevated Side Effect Profile in Phase 3 Trials
INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…
Read More
Eli Lilly and Oura Health Forge Strategic Alliance to Pioneer Integrated Obesity Care
The landscape of obesity treatment is undergoing a profound transformation, moving beyond purely pharmaceutical interventions to embrace a holistic ecosystem…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy
NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…
Read More
Eli Lilly’s Retatrutide Shows Unprecedented Weight Loss, But Increased Side Effects Raise Tolerability Concerns
Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
